245 related articles for article (PubMed ID: 32100468)
1. Cardiomyopathy and kidney function in agalsidase beta-treated female Fabry patients: a pre-treatment vs. post-treatment analysis.
Wanner C; Feldt-Rasmussen U; Jovanovic A; Linhart A; Yang M; Ponce E; Brand E; Germain DP; Hughes DA; Jefferies JL; Martins AM; Nowak A; Vujkovac B; Weidemann F; West ML; Ortiz A
ESC Heart Fail; 2020 Jun; 7(3):825-834. PubMed ID: 32100468
[TBL] [Abstract][Full Text] [Related]
2. Clinical outcomes among young patients with Fabry disease who initiated agalsidase beta treatment before 30 years of age: An analysis from the Fabry Registry.
Hopkin RJ; Cabrera GH; Jefferies JL; Yang M; Ponce E; Brand E; Feldt-Rasmussen U; Germain DP; Guffon N; Jovanovic A; Kantola I; Karaa A; Martins AM; Tøndel C; Wilcox WR; Yoo HW; Burlina AP; Mauer M
Mol Genet Metab; 2023 Feb; 138(2):106967. PubMed ID: 36709533
[TBL] [Abstract][Full Text] [Related]
3. Agalsidase therapy in patients with Fabry disease on renal replacement therapy: a nationwide study in Italy.
Mignani R; Feriozzi S; Pisani A; Cioni A; Comotti C; Cossu M; Foschi A; Giudicissi A; Gotti E; Lozupone VA; Marchini F; Martinelli F; Bianco F; Panichi V; Procaccini DA; Ragazzoni E; Serra A; Soliani F; Spinelli L; Torti G; Veroux M; Cianciaruso B; Cagnoli L
Nephrol Dial Transplant; 2008 May; 23(5):1628-35. PubMed ID: 18057066
[TBL] [Abstract][Full Text] [Related]
4. Long-Term Dose-Dependent Agalsidase Effects on Kidney Histology in Fabry Disease.
Skrunes R; Tøndel C; Leh S; Larsen KK; Houge G; Davidsen ES; Hollak C; van Kuilenburg ABP; Vaz FM; Svarstad E
Clin J Am Soc Nephrol; 2017 Sep; 12(9):1470-1479. PubMed ID: 28625968
[TBL] [Abstract][Full Text] [Related]
5. Effects of Baseline Left Ventricular Hypertrophy and Decreased Renal Function on Cardiovascular and Renal Outcomes in Patients with Fabry Disease Treated with Agalsidase Alfa: A Fabry Outcome Survey Study.
Feriozzi S; Linhart A; Ramaswami U; Kalampoki V; Gurevich A; Hughes D;
Clin Ther; 2020 Dec; 42(12):2321-2330.e0. PubMed ID: 33218740
[TBL] [Abstract][Full Text] [Related]
6. Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease.
Germain DP; Charrow J; Desnick RJ; Guffon N; Kempf J; Lachmann RH; Lemay R; Linthorst GE; Packman S; Scott CR; Waldek S; Warnock DG; Weinreb NJ; Wilcox WR
J Med Genet; 2015 May; 52(5):353-8. PubMed ID: 25795794
[TBL] [Abstract][Full Text] [Related]
7. Agalsidase alfa: a review of its use in the management of Fabry disease.
Keating GM
BioDrugs; 2012 Oct; 26(5):335-54. PubMed ID: 22946754
[TBL] [Abstract][Full Text] [Related]
8. The effectiveness of long-term agalsidase alfa therapy in the treatment of Fabry nephropathy.
Feriozzi S; Torras J; Cybulla M; Nicholls K; Sunder-Plassmann G; West M;
Clin J Am Soc Nephrol; 2012 Jan; 7(1):60-9. PubMed ID: 22246281
[TBL] [Abstract][Full Text] [Related]
9. Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation.
Warnock DG; Ortiz A; Mauer M; Linthorst GE; Oliveira JP; Serra AL; Maródi L; Mignani R; Vujkovac B; Beitner-Johnson D; Lemay R; Cole JA; Svarstad E; Waldek S; Germain DP; Wanner C;
Nephrol Dial Transplant; 2012 Mar; 27(3):1042-9. PubMed ID: 21804088
[TBL] [Abstract][Full Text] [Related]
10. Patients with Fabry Disease after Enzyme Replacement Therapy Dose Reduction and Switch-2-Year Follow-Up.
Lenders M; Canaan-Kühl S; Krämer J; Duning T; Reiermann S; Sommer C; Stypmann J; Blaschke D; Üçeyler N; Hense HW; Brand SM; Wanner C; Weidemann F; Brand E
J Am Soc Nephrol; 2016 Mar; 27(3):952-62. PubMed ID: 26185201
[TBL] [Abstract][Full Text] [Related]
11. Antiproteinuric therapy and Fabry nephropathy: factors associated with preserved kidney function during agalsidase-beta therapy.
Warnock DG; Thomas CP; Vujkovac B; Campbell RC; Charrow J; Laney DA; Jackson LL; Wilcox WR; Wanner C
J Med Genet; 2015 Dec; 52(12):860-6. PubMed ID: 26490103
[TBL] [Abstract][Full Text] [Related]
12. Enzyme replacement therapy for Anderson-Fabry disease.
El Dib R; Gomaa H; Carvalho RP; Camargo SE; Bazan R; Barretti P; Barreto FC
Cochrane Database Syst Rev; 2016 Jul; 7(7):CD006663. PubMed ID: 27454104
[TBL] [Abstract][Full Text] [Related]
13. Safety and effectiveness of enzyme replacement therapy with agalsidase alfa in patients with Fabry disease: Post-marketing surveillance in Japan.
Sasa H; Nagao M; Kino K
Mol Genet Metab; 2019 Apr; 126(4):448-459. PubMed ID: 30803893
[TBL] [Abstract][Full Text] [Related]
14. Cardio- Renal Outcomes With Long- Term Agalsidase Alfa Enzyme Replacement Therapy: A 10- Year Fabry Outcome Survey (FOS) Analysis.
Ramaswami U; Beck M; Hughes D; Kampmann C; Botha J; Pintos-Morell G; West ML; Niu DM; Nicholls K; Giugliani R;
Drug Des Devel Ther; 2019; 13():3705-3715. PubMed ID: 31749608
[TBL] [Abstract][Full Text] [Related]
15. Analysis of Renal and Cardiac Outcomes in Male Participants in the Fabry Outcome Survey Starting Agalsidase Alfa Enzyme Replacement Therapy Before and After 18 Years of Age.
Parini R; Pintos-Morell G; Hennermann JB; Hsu TR; Karabul N; Kalampoki V; Gurevich A; Ramaswami U;
Drug Des Devel Ther; 2020; 14():2149-2158. PubMed ID: 32581513
[TBL] [Abstract][Full Text] [Related]
16. Switch from agalsidase beta to agalsidase alfa in the enzyme replacement therapy of patients with Fabry disease in Latin America.
Ripeau D; Amartino H; Cedrolla M; Urtiaga L; Urdaneta B; Cano M; Valdez R; Antongiovanni N; Masllorens F
Medicina (B Aires); 2017; 77(3):173-179. PubMed ID: 28643672
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years' treatment.
Kampmann C; Perrin A; Beck M
Orphanet J Rare Dis; 2015 Sep; 10():125. PubMed ID: 26416388
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of enzyme-replacement-therapy with agalsidase alfa in 36 treatment-naïve Fabry disease patients.
Tsuboi K; Yamamoto H
BMC Pharmacol Toxicol; 2017 Jun; 18(1):43. PubMed ID: 28592315
[TBL] [Abstract][Full Text] [Related]
19. Antiproteinuric therapy and fabry nephropathy: sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase-beta.
Tahir H; Jackson LL; Warnock DG
J Am Soc Nephrol; 2007 Sep; 18(9):2609-17. PubMed ID: 17656478
[TBL] [Abstract][Full Text] [Related]
20. Usefulness of tissue Doppler on early detection of cardiac disease in Fabry patients and potential role of enzyme replacement therapy (ERT) for avoiding progression of disease.
Zamorano J; Serra V; Pérez de Isla L; Feltes G; Calli A; Barbado FJ; Torras J; Hernandez S; Herrera J; Herrero JA; Pintos G
Eur J Echocardiogr; 2011 Sep; 12(9):671-7. PubMed ID: 21810826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
